SNP 1772 C > T of HIF-1α gene associates with breast cancer risk in a Taiwanese population

Cancer Cell International

Hsueh-Wei Chang³  Sheng-Fung Lin¹  Yi-Hsing Yang⁴  Chee-Yin Chai²  Ming-Feng Hou³  Shi-Long Lian⁵  Chih-Jen Huang⁵ 

[1] Department of Medical Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

关键词: Survival;    Association study;    Breast cancer;    SNPs;    HIF-1α;   

Others  :  1121654
DOI  :  10.1186/s12935-014-0087-7

 received in 2014-04-13, accepted in 2014-08-25,  发布年份 2014

【 摘 要 】

Background

Hypoxia inducible factor 1α (HIF-1α) is a stress-responsive transcription factor to hypoxia and its expression is correlated to tumor progression and angiogenesis. Several single nucleotide polymorphisms (SNPs) of HIF-1α gene in the oxygen-dependent degradation (ODD) domain was reportedly associated with increased HIF-1α activity.

Results

In this study, we focused on the relationship between SNP 1772 C > T (rs11549465) of HIF-1α gene and its breast cancer risk, as well as its correlation with HIF-1α expression and tumor angiogenesis. Ninety six breast cancer patients and 120 age-matched controls were enrolled. We found that 1772 T allele of HIF-1α gene was associated with increased breast cancer risk (adjusted OR = 14.51; 95% CI: 6.74-31.24). This SNP was not associated with clinicopathologic features of angiogenesis such as VEGF activity and the micro-vessel density and survival of breast cancer patients.

Conclusion

Taken together, the 1772 C > T of HIF-1α gene is a potential biomarker for breast cancer susceptibility.

【 授权许可】

   
2014 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Chuang LY, Yang CH, Tsui KH, Cheng YH, Chang PL, Wen CH, Chang HW: Restriction enzyme mining for SNPs in genomes. Anticancer Res 2008, 28(4A):2001-2007.
• [2]Cantor CR: The use of genetic SNPs as new diagnostic markers in preventive medicine. Ann N Y Acad Sci 2005, 1055:48-57.
• [3]Chang HW, Chuang LY, Tsai MT, Yang CH: The importance of integrating SNP and cheminformatics resources to pharmacogenomics. Curr Drug Metab 2012, 13(7):991-999.
• [4]Liu SG, Gao C, Zhang RD, Jiao Y, Cui L, Li WJ, Chen ZP, Wu MY, Zheng HY, Zhao XX, Yue ZX, Li ZG: FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Cell Int 2013, 13(1):107. BioMed Central Full Text
• [5]Ding H, Jing X, Ding N, Fu Z, Song Y, Zhu J: Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma. Cancer Cell Int 2013, 13(1):58. BioMed Central Full Text
• [6]Lin HJ, Kung YJ, Lin YJ, Sheu JJ, Chen BH, Lan YC, Lai CH, Hsu YA, Wan L, Tsai FJ: Association of the lumican gene functional 3′-UTR polymorphism with high myopia. Invest Ophthalmol Vis Sci 2010, 51(1):96-102.
• [7]Kuo HC, Yang KD, Juo SH, Liang CD, Chen WC, Wang YS, Lee CH, Hsi E, Yu HR, Woon PY, Lin IC, Huang CF, Hwang DY, Lee CP, Lin LY, Chang WP, Chang WC: ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One 2011, 6(4):e17370.
• [8]Hwang CW, Lu CH, Sun SF, Sung TY, Chung HY, Huang SY, Hung HC, Chen CH, Sun YM, Lin YY, Liu WS, Wen ZH: Comprehensive association analysis of 10 single nucleotide polymorphisms associated with osteoporosis among a Taiwanese population. Int J Hum Genet 2011, 11(4):249-257.
• [9]Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS, Huang CJ, Wang CL, Chang HW: Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 2009, 13(2):165-172.
• [10]Chen FM, Ou-Yang F, Yang SF, Tsai EM, Hou MF: P53 codon 72 polymorphism in Taiwanese breast cancer patients. Kaohsiung J Med Sci 2013, 29(5):259-264.
• [11]Chang WC, Woon PY, Hsu YW, Yang S, Chiu YC, Hou MF: The association between single-nucleotide polymorphisms of ORAI1 gene and breast cancer in a Taiwanese population. ScientificWorldJournal 2012, 2012:916587.
• [12]Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
• [13]Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93(4):309-314.
• [14]Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V: Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004, 6(3):R191-R198. BioMed Central Full Text
• [15]Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88(4):1474-1480.
• [16]Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107(1):43-54.
• [17]Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-472.
• [18]Ollerenshaw M, Page T, Hammonds J, Demaine A: Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 2004, 153(2):122-126.
• [19]Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER: The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 2001, 20(36):5067-5074.
• [20]Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M: Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003, 24(11):1779-1783.
• [21]Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ: The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007, 67(1):8-13.
• [22]Kuo WH, Shih CM, Lin CW, Cheng WE, Chen SC, Chen W, Lee YL: Association of hypoxia inducible factor-1alpha polymorphisms with susceptibility to non-small-cell lung cancer. Transl Res 2012, 159(1):42-50.
• [23]Ruiz-Tovar J, Fernandez-Contreras ME, Martin-Perez E, Gamallo C: Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer. Tumori 2012, 98(3):364-369.
• [24]Yang X, Zhu HC, Zhang C, Qin Q, Liu J, Xu LP, Zhao LJ, Zhang Q, Cai J, Ma JX, Cheng HY, Sun XC: HIF-1alpha 1772 C/T and 1790 G/A polymorphisms are significantly associated with higher cancer risk: an updated meta-analysis from 34 case–control studies. PLoS One 2013, 8(11):e80396.
• [25]Prchal JT: Delivery on demand–a new era of gene therapy? N Engl J Med 2003, 348(13):1282-1283.
• [26]Huang CJ, Hou MF, Lin SD, Chuang HY, Huang MY, Fu OY, Lian SL: Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction. Plast Reconstr Surg 2006, 118(5):1079-1086. discussion 1087–1078
• [27]Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160(4):1223-1228.
• [28]Chang HW, Cheng CA, Gu DL, Chang CC, Su SH, Wen CH, Chou YC, Chou TC, Yao CT, Tsai CL, Cheng CC: High-throughput avian molecular sexing by SYBR green-based real-time PCR combined with melting curve analysis. BMC Biotechnol 2008, 8:12. BioMed Central Full Text
• [29]Chang HW, Cheng YH, Chuang LY, Yang CH: SNP-RFLPing 2: an updated and integrated PCR-RFLP tool for SNP genotyping. BMC Bioinformatics 2010, 11:173. BioMed Central Full Text
• [30]Chang HW, Yang CH, Chang PL, Cheng YH, Chuang LY: SNP-RFLPing: restriction enzyme mining for SNPs in genomes. BMC Genomics 2006, 7(1):30. BioMed Central Full Text
• [31]Yang CH, Cheng YH, Chuang LY, Chang HW: Drug-SNPing: an integrated drug-based, protein interaction-based tagSNP-based pharmacogenomics platform for SNP genotyping. Bioinformatics 2013, 29(6):758-764.
• [32]Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY: Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 2005, 35(4):207-213.
• [33]Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835.
• [34]Kuwai T, Kitadai Y, Tanaka S, Kuroda T, Ochiumi T, Matsumura S, Oue N, Yasui W, Kaneyasu M, Tanimoto K, Nishiyama M, Chayama K: Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep 2004, 12(5):1033-1037.
• [35]Fu SL, Miao J, Ding B, Wang XL, Cheng WJ, Dai HH, Han SP: A polymorphism in the 3′ untranslated region of Hypoxia-Inducible Factor-1 alpha confers an increased risk of cervical cancer in a Chinese population. Neoplasma 2014, 61(1):63-69.
• [36]Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272(36):22642-22647.
• [37]Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399(6733):271-275.
• [38]Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 2001, 20(18):5197-5206.
• [39]Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP: Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 2002, 296(5574):1886-1889.
• [40]Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS: A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol Cancer 2003, 2:31. BioMed Central Full Text
• [41]Vleugel MM, Greijer AE, van der Wall E, van Diest PJ: Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer. Cancer Genet Cytogenet 2005, 163(2):168-172.
• [42]Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97(6):1573-1581.
• [43]Goncalves R, Bose R: Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013, 11(2):174-182. quiz 182
• [44]Yang CH, Chuang LY, Cheng YH, Lin YD, Wang CL, Wen CH, Chang HW: Single nucleotide polymorphism barcoding to evaluate oral cancer risk using odds ratio-based genetic algorithms. Kaohsiung J Med Sci 2012, 28(7):362-368.
• [45]Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW: Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med 2008, 37(5):271-277.
• [46]Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008, 358(9):910-919.
• [47]Vogelsang M, Wang Y, Veber N, Mwapagha LM, Parker MI: The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS One 2012, 7(5):e36962.
• [48]Chang WC, Fang YY, Chang HW, Chuang LY, Lin YD, Hou MF, Yang CH: Identifying association model for single-nucleotide polymorphisms of ORAI1 gene for breast cancer. Cancer Cell Int 2014, 14(1):29. BioMed Central Full Text